⌘K
t
Diaceutics PLC provided a block listing return for its UK and Global Share Incentive Plan, Employee Share Option Plan, and Unapproved Share Option Plan. For the period from 7 October 2025 to 6 April 2026, 23,588 Ordinary Shares were issued or allotted under these schemes. At the end of the period, 1,233,063 Ordinary Shares remained unissued under the schemes, and the total number of Ordinary Shares in issue was 84,917,283.
| Date | 7 Apr 2026 |
| Time | 07:00:11 |
| Category | Miscellaneous |
| ID | 0994Z |
Diaceutics PLC
BLOCK LISTING RETURN
New York, Belfast and London, 7 April 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long term incentive awards.
|
Name of applicant: |
Diaceutics PLC |
|||
|
Name of scheme: |
UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long-term incentive awards. |
|||
|
Period of return: |
From: |
7 October 2025 |
To: |
6 April 2026 |
|
Balance under scheme from previous return: |
1,256,651 Ordinary Shares of £0.002 each |
|||
|
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: |
N/A |
|||
|
Number of securities issued/allotted under schemes during period: |
23,588 Ordinary Shares
|
|||
|
Balance under scheme not yet issued/allotted at end of period |
1,233,063 Ordinary Shares |
|||
|
Number and class of securities originally listed and the date of admission |
1,500,000 Ordinary Shares on 6 October 2023 |
|||
|
Total number of securities in issue at the end of the period |
84,917,283 Ordinary Shares of £0.002 each |
|||
|
Name of contact: |
Nick Roberts |
|||
|
Telephone number of contact: |
As below |
|||
Enquiries:
|
Diaceutics PLC |
|
|
Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.